🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsHas anyone dealt with compounded sema dosing calculator?

Has anyone dealt with compounded sema dosing calculator?

AttorneyGrant Wed, Sep 10, 2025 at 10:50 AM 26 replies 1,412 viewsPage 1 of 6
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
Sep 10, 2025 at 10:50 AM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I actually want to know is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. I have searched first, so if this is covered somewhere point me at it and I will read it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
7 2Dr.SleepRoch, laura_annarbor, JenMemphis and 4 others
Reply Quote Save Share Report
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Sep 10, 2025 at 11:14 AM#2
AttorneyGrant said:
They are two different exemptions from the same federal requirements and they buy different things.

Agreeing with AttorneyGrant, and the qualification matters more than the agreement. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Happy to go further on any of that.

Last edited: Sep 10, 2025 at 2:14 PM
6 1MikeNYC_runner and 3 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Sep 10, 2025 at 11:38 AM#3
AttorneyGrant said:
They are two different exemptions from the same federal requirements and they buy different things.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

5 0MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 2 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Sep 10, 2025 at 12:02 PM#4

Taking the question as asked, rather than the general version of it. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

4 24LindaRN_retired, tommy_boulder, hyun_seoul and 1 other
Reply Quote Save Share Report
pete_RVA
Member
178
890
Dec 2024
Richmond, VA
Sep 10, 2025 at 2:14 PM#5
PurityPaulOR said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

Last edited: Sep 10, 2025 at 7:14 PM
3 23Dr.LeslieOBGYN, MikeNYC_runner
Reply Quote Save Share Report
1236

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register